

427.098

10/550122

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Patent Application of  
Lydie Poitout, et al:  
Serial No.:  
Filed: Concurrently herewith  
For: IMIDAZOPYRIDINE...AGONISTS

September 19, 2005


INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria VA 22313-1450

Sir:

To comply with Rule 56, applicants are submitting herewith copies of the prior art that is pertinent to the above application and PTO form SB/08A. No preliminary examination report has issued yet in the corresponding PCT application.

Respectfully submitted,

  
Charles A. Muserlian, Reg. 19,683  
Hedman & Costigan, PC  
1185 Avenue of the Americas  
New York, NY 10036  
Tel# (212)302-8989

CAM:dn

JC05 Rec'd PCT/PTO 19 SEP 2005

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
A collection of four (4) pages.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

**Substitute for form 1449/PTO**

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

**(Use as many sheets as necessary)**

Sheet 1

of 1

**Complete if Known**

**Application Number**

**Filing Date**

---

**First Named Inventor**

## Art Unit

**Examiner Name**

10/550122  
Lester Pottlitz

Attorney Docket Number 427 098

**U. S. PATENT DOCUMENTS**

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	FOREIGN PATENT DOCUMENTS			
		Foreign Patent Document Country Code <sup>2</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
		PCT/US01/48855	08/08/2002	Vertex Pharmaceuticals Inc.	
		PCT/US01/17014	12/06/2001	Merck & Co., Inc.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.